PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
Main Authors: | , , , , , , , , , , , , , , |
---|---|
格式: | 文件 |
语言: | English |
出版: |
Wiley
2022-08-01
|
丛编: | HemaSphere |
在线阅读: | http://journals.lww.com/10.1097/01.HS9.0000872868.40573.13 |